MedPage Today on MSN
Dual GIP/GLP-1 Drug Linked to Fewer Deaths in Real-World Liver Disease Study
P HOENIX -- Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, ...
MedPage Today on MSN
GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes
O RLANDO -- Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective cohort study linked GLP-1 receptor agonists to a lower risk of legal blindness ...
MedPage Today on MSN
How Do GLP-1 Drugs Stack Up for Cardiorenal Benefits in Diabetes?
"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...
MedPage Today on MSN
Real-World Data Back GLP-1s in Asthma, Cardiopulmonary Conditions
CHICAGO -- A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST ...
Along with cost, education around total rewards is also a part of the Q4 benefits conversation.
Five systemic drugs, including fingolimod and apixaban, were identified with under-recognized maculopathy risks using ...
Paclitaxel-coated vs. uncoated devices did not reduce amputations in patients with chronic limb-threatening ischemia and ...
Treatment of significant musculoskeletal symptoms with NSAIDs may be acceptable for certain patients with inflammatory bowel disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback